Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

The expanding role of SGLT2 inhibitors in glucose-lowering and cardio-renal protection

Tools
- Tools
+ Tools

Brown, Emily, Wilding, John P. H. , Alam, Uazman, Barber, Thomas M., Karalliedde, Janaka and Cuthbertson, Daniel J. (2021) The expanding role of SGLT2 inhibitors in glucose-lowering and cardio-renal protection. Annals of Medicine, 53 (1). pp. 2072-2089. doi:10.1080/07853890.2020.1841281

[img]
Preview
PDF
WRAP-expanding-role-SGLT2-inhibitors-glucose-lowering-cardio-renal-protection-Barber-2020.pdf - Accepted Version - Requires a PDF viewer.
Available under License Creative Commons Attribution 4.0.

Download (1265Kb) | Preview
Official URL: https://doi.org/10.1080/07853890.2020.1841281

Request Changes to record.

Abstract

The kidney plays a major physiological role in glucose homeostasis but also contributes to the pathophysiology of type 2 diabetes (T2D), mediated by renal sodium glucose cotransporters (SGLTs). This recognition led to development of SGLT2 inhibitors that inhibit proximal renal tubular renal glucose and sodium reabsorption. The glucoretic and natriuretic effect of SGLT2 inhibitors is associated with reductions in HbA1c levels, body weight, systolic blood pressure and triglycerides.

Major vascular complications of T2D include cardiovascular disease and chronic kidney disease (CKD). Results from several cardiovascular outcome trials (CVOTs) with these drugs have highlighted benefits in reducing major adverse cardiovascular events by 11%, reducing the risk of cardiovascular death or hospitalisation for heart failure (HF) by 23% and reducing risk of progression of renal disease by 45%. Their cardiorenal benefits are apparent across a range of eGFRs (within CKD1-3 groups) and the presence or absence of ischaemic heart disease, HF or T2D. In patients with HF with reduced ejection fraction (HFrEF), similar risk reductions in cardiovascular death and HF events are also seen; results from studies in patients with HF with preserved ejection fraction (HFpEF) are awaited. Cardiorenal benefits have been recently reported in patients with CKD, regardless of the presence or absence of T2D.

Indications for use of SGLT2 inhibitors has extended beyond glucose-lowering to a central role in cardiorenal protection. This review will first explore the mechanisms by which glycaemic control, weight loss and cardiovascular risk factors are modulated therapeutically with SGLT2 inhibitors. Subsequently we outline putative mechanisms underpinning the cardiorenal benefits seen, including in HF and CKD, in the context of completed and ongoing clinical studies. Treatment strategies with SGLT2 inhibitors in individuals with CKD or HF, with and/or without T2D are increasingly appealing. Combination therapy with complementary therapeutic agents is also explored.

Item Type: Journal Article
Subjects: R Medicine > RA Public aspects of medicine
R Medicine > RC Internal medicine
Divisions: Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Biomedical Sciences
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine > Metabolic and Vascular Health (- until July 2016)
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Diabetes, Kidneys -- Diseases, Non-insulin-dependent diabetes -- Treatment, Glucose -- Metabolism, Homeostasis
Journal or Publication Title: Annals of Medicine
Publisher: Taylor & Francis
ISSN: 0785-3890
Official Date: 2021
Dates:
DateEvent
2021Published
27 October 2020Available
21 October 2020Accepted
Volume: 53
Number: 1
Page Range: pp. 2072-2089
DOI: 10.1080/07853890.2020.1841281
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access
Related URLs:
  • Publisher

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us